European Journal of Heart Failure Publishes Pre-Specified Sub-Group Analysis of Heart Failure Patients With Hyperkalemia From Phase 3 Trial of Patiromer FOS
October 13, 2015 at 16:31 PM EDT
Relypsa Inc. (NASDAQ: RLYP), a biopharmaceutical company, today announced that results of a pre-specified sub-group analysis from the ...